Toxicogenomics and cross-species biomarker discovery: Applications in drug discovery and safety assessment

Toxicology Mechanisms and Methods

Volumn 16, Issue 2-3, 2006, Pages 79-87

  Orr, Michael S ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Cross Species Biomarkers; Toxicogenomics

Indexed keywords

BENZO[A]PYRENE; BIOLOGICAL MARKER; CLOFIBRATE; DICLOFENAC; GEMFIBROZIL; INDOMETACIN; PARACETAMOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHENOBARBITAL;

CARCINOGENICITY; COST EFFECTIVENESS ANALYSIS; DATA BASE; DNA MICROARRAY; DOWN REGULATION; DRUG INDUCED CANCER; DRUG INDUSTRY; DRUG SAFETY; GENE IDENTIFICATION; GENETIC ANALYSIS; GENETIC TOXICOLOGY; GENOME ANALYSIS; GENOMICS; HEPATITIS; HUMAN; LIVER FIBROSIS; LIVER TOXICITY; MICROARRAY ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; TOXICOGENETICS;

CANIS FAMILIARIS;

EID: 33645001951     PISSN: 15376516     EISSN: 15376524     Source Type: Journal    
DOI: 10.1080/15376520600558317     Document Type: Review

References (46)

1. Aardema, M. J., and MacGregor, J. T. 2002. Toxicology and genetic toxicology in the new era of "toxicogenomics": Impact of "-omics" technologies. Mutat. Res. 499(1):13-25.
2. Afshari, C. A., Nuwaysir, E. F., and Barrett, J. C. 1999. Application of complementary DNA microarray technology to carcinogen identification, toxicology, and drug safety evaluation. Cancer Res. 59(19):4759-4760.
3. Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., Powell, J. I., Yang, L., Marti, G. E., Moore, T., Hudson, J., Jr., Lu, L., Lewis, D. B., Tibshirani, R., Sherlock, G., Chan, W. C., Greiner, T. C., Weisenburger, D. D., Armitage, J. O., Warnke, R., Levy, R., Wilson, W., Grever, M. R., Byrd, J. C., Botstein, D., Brown, P. O., and Staudt, L. M. 2000. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [see comments]. Nature 403(6769):503-511.
4. Bataller, R., and Brenner, D. A. 2005. Liver fibrosis. J. Clin. Invest. 115(2):209-218.
5. Bittner, M., Meltzer, P., Chen, Y., Jiang, Y., Seftor, E., Hendrix, M., Radmacher, M., Simon, R., Yakhini, Z., Ben-Dor, A., Sampas, N., Dougherty, E., Wang, E., Marincola, F., Gooden, C., Lueders, J., Glatfelter, A., Pollock, P., Carpten, J., Gillanders, E., Leja, D., Dietrich, K., Beaudry, C., Berens, M., Alberts, D., and Sondak, V. 2000. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406(6795):536-540.
6. Bulera, S. J., Eddy, S. M., Ferguson, E., Jatkoe, T. A., Reindel, J. F., Bleavins, M. R., and De La Iglesia, F. A. 2001. RNA expression in the early characterization of hepatotoxicants in Wistar rats by high-density DNA microarrays. Hepatology 33(5):1239-1258.
7. Burczynski, M. E., McMillian, M., Ciervo, J., Li, L., Parker, J. B., Dunn, R. T., 2nd, Hicken, S., Farr, S., and Johnson, M. D. 2000. Toxicogenomics-based discrimination of toxic mechanism in HepG2 human hepatoma cells. Toxicol. Sci. 58(2):399-415.
8. Cunningham, M. L., and Lehman-McKeeman, L. 2005. Applying toxicogenomics in mechanistic and predictive toxicology. Toxicol. Sci. 83(2):205-206.
9. Farr, S., and Dunn, R. T., 2nd. 1999. Concise review: Gene expression applied to toxicology. Toxicol Sci 50(1):1-9.
10. Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. 1987. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med. 317(20):1237-1245.
11. Fuhrman, S., Cunningham, M. J., Wen, X., Zweiger, G., Seilhamer, J. J., and Somogyi, R., 2000. The application of shannon entropy in the identification of putative drug targets. Biosystems 55(1-3):5-14.
12. Garrett, M. D., and Workman, P. 1999. Discovering novel chemotherapeutic drugs for the third millennium. Eur. J. Cancer. 35(14):2010-2030.
13. Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., Bloomfield, C. D., and Lander, E. S. 1999. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. Science 286(5439):531-537.
14. Gonzalez, F. J., Peters, J. M., and Cattley, R. C. 1998. Mechanism of action of the nongenotoxic peroxisome proliferators: Role of the peroxisome proliferator-activator receptor alpha. J. Natl. Cancer. Inst. 90(22):1702-1709.
15. Hamadeh, H. K., Bushel, P. R., Jayadev, S., DiSorbo, O., Bennett, L., Li, L., Tennant, R., Stoll, R., Barrett, J. C., Paules, R. S., Blanchard, K., and Afshari, C. A. 2002. Prediction of compound signature using high density gene expression profiling. Toxicol. Sci. 67(2):232-240.
16. Hamadeh, H. K., Bushel, P. R., Jayadev, S., Martin, K., DiSorbo, O., Sieber, S., Bennett, L., Tennant, R., Stoll, R., Barrett, J. C., Blanchard, K., Paules, R. S., and Afshari, C. A. 2002. Gene expression analysis reveals chemical-specific profiles. Toxicol. Sci. 67(2):219-231.
17. Hamadeh, H. K., Knight, B. L., Haugen, A. C., Sieber, S., Amin, R. P., Bushel, P. R., Stoll, R., Blanchard, K., Jayadev, S., Tennant, R. W., Cunningham, M. L., Afshari, C. A., and Paules, R. S. 2002. Methapyrilene toxicity: Anchorage of pathologic observations to gene expression alterations. Toxicol. Pathol. 30(4):470-482.
18. Hertz, R., and Bar-Tana, J. 1998. Peroxisome proliferator-activated receptor (PPAR) alpha activation and its consequences in humans. Toxicol. Lett. 102-103:85-90.
19. Huang, Q., Dunn, R. T., 2nd, Jayadev, S., DiSorbo, O., Pack, F. D., Farr, S. B., Stoll, R. E., and Blanchard, K. T. 2001. Assessment of cisplatin-induced nephrotoxicity by microarray technology. Toxicol. Sci. 63(2):196-207.
20. Lesko, L. J., and Atkinson, A. J., Jr. 2001. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: Criteria, validation, strategies. Annu. Rev. Pharmacol. Toxicol. 41:347-366.
21. Madias, N. E., and Harrington, J. T. 1978. Platinum nephrotoxicity. Am. J. Med. 65(2):307-314.
22. Naveau, S., Raynard, B., Ratziu, V., Abella, A., Imbert-Bismut, F., Messous, D., Beuzen, F., Capron, F., Thabut, D., Munteanu, M., Chaput, J. C., and Poynard, T. 2005. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin. Gastroenterol Hepatol. 3(2):167-174.
23. Nuwaysir, E. F., Bittner, M., Trent, J., Barrett, J. C., and Afshari, C. A. 1999. Microarrays and toxicology: The advent of toxicogenomics. Mol. Carcinog. 24(3):153-159.
24. Palmer, C. N., Hsu, M. H., Griffin, K. J., Raucy, J. L., and Johnson, E. F. 1998. Peroxisome proliferator activated receptor-alpha expression in human liver. Mol. Pharmacol. 53(1):14-22.
25. Perou, C. M., Sorlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., Fluge, O., Pergamenschikov, A., Williams, C., Zhu, S. X., Lonning, P. E., Borresen-Dale, A. L., Brown, P. O., and Botstein, D. 2000. Molecular portraits of human breast tumours. Nature 406(6797):747-752.
26. Peters, J. M., Cattley, R. C., and Gonzalez, F. J. 1997. Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. Carcinogenesis 18(11):2029-2033.
27. Poynard, T., Abella, A., Pignon, J. P., Naveau, S., Leluc, R., and Chaput, J. C. 1986. Apolipoprotein AI and alcoholic liver disease. Hepatology 6(6):1391-1395.
28. Poynard, T., Aubert, A., Bedossa, P., Abella, A., Naveau, S., Paraf, F., and Chaput, J. C. 1991. A simple biological index for detection of alcoholic liver disease in drinkers. Gastroenterology 100(5 Pt 1):1397-1402.
29. Poynard, T., Imbert-Bismut, F., Munteanu, M., Messous, D., Myers, R. P., Thabut, D., Ratziu, V., Mercadier, A., Benhamou, Y., and Hainque, B. 2004. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp. Hepatol. 3(1):8.
30. Poynard, T., Imbert-Bismut, F., Munteanu, M., and Ratziu, V. 2005. FibroTest-FibroSURE: Towards a universal biomarker of liver fibrosis? Expert. Rev. Mol. Diagn. 5(1):15-21.
31. Roberts, R. A. 1999. Peroxisome proliferators: Mechanisms of adverse effects in rodents and molecular basis for species differences. Arch. Toxicol. 73(8-9):413-418.
32. Ruepp, S., Boess, F., Suter, L., de Vera, M. C., Steiner, G., Steele, T., Weiser, T., and Albertini, S. 2005. Assessment of hepatotoxic liabilities by transcript profiling. Toxicol. Appl. Pharmacol. 207(2 Suppl):161-170.
33. Schena, M., Heller, R. A., Theriault, T. P., Konrad, K., Lachenmeier, E., and Davis, R. W. 1998. Microarrays: Biotechnology's discovery platform for functional genomics. Trends Biotechnol. 16(7):301-306.
34. Scherf, U., Ross, D. T., Waltham, M., Smith, L. H., Lee, J. K., Tanabe, L., Kohn, K. W., Reinhold, W. C., Myers, T. G., Andrews, D. T., Scudiero, D. A., Eisen, M. B., Sausville, E. A., Pommier, Y., Botstein, D., Brown, P. O., and Weinstein, J. N. 2000. A gene expression database for the molecular pharmacology of cancer. Nat. Genet. 24(3):236-244.
35. Steiner, G., Suter, L., Boess, F., Gasser, R., de Vera, M. C., Albertini, S., and Ruepp, S. 2004. Discriminating different classes of toxicants by transcript profiling. Environ. Health Perspect. 112(12):1236-1248.
36. Suter, L., Babiss, L. E., and Wheeldon, E. B. 2004. Toxicogenomics in predictive toxicology in drug development. Chem. Biol. 11(2):161-171.
37. Suter, L., Haiker, M., De Vera, M. C., and Albertini, S. 2003. Effect of two 5-HT6 receptor antagonists on the rat liver: A molecular approach. Pharmacogenomics J. 3(6):320-334.
38. Teare, J. P., Sherman, D., Greenfield, S. M., Simpson, J., Bray, G., Catterall, A. P., Murray-Lyon, I. M., Peters, T. J., Williams, R., and Thompson, R. P. 1993. Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis. Lancet 342(8876):895-898.
39. Thomas, R. S., Rank, D. R., Penn, S. G., Zastrow, G. M., Hayes, K. R., Pande, K., Glover, E., Silander, T., Craven, M. W., Reddy, J. K., Jovanovich, S. B., and Bradfield, C. A. 2001. Identification of toxicologically predictive gene sets using cDNA microarrays. Mol. Pharmacol. 60(6):1189-1194.
40. Thukral, S. K., Nordone, P. J., Hu, R., Sullivan, L., Galambos, E., Fitzpatrick, V. D., Healy, L., Bass, M. B., Cosenza, M. E., and Afshari, C. A. 2005. Prediction of nephrotoxicant action and identification of candidate toxicity-related biomarkers. Toxicol. Pathol. 33(3):343-355.
41. Tugwood, J. D., Aldridge, T. C., Lambe, K. G., Macdonald, N., and Woodyatt, N. J. 1996. Peroxisome proliferator-activated receptors: Structures and function. Ann. N.Y. Acad. Sci. 804:252-265.
42. Vogelzang, N. J. 1991. Nephrotoxicity from chemotherapy: Prevention and management. Oncology (Williston Park) 5(10):97-102, 105; disc 105, 109-111.
43. Waring, J. F., Ciurlionis, R., Jolly, R. A., Heindel, M., and Ulrich, R. G. 2001. Microarray analysis of hepatotoxins in vitro reveals a correlation between gene expression profiles and mechanisms of toxicity. Toxicol. Lett. 120(1-3):359-368.
44. Waring, J. F., Jolly, R. A., Ciurlionis, R., Lum, P. Y., Praestgaard, J. T., Morfitt, D. C., Buratto, B., Roberts, C., Schadt, E., and Ulrich, R. G. 2001. Clustering of hepatotoxins based on mechanism of toxicity using gene expression profiles. Toxicol. Appl. Pharmacol. 175(1):28-42.
45. Waring, J. F., and Ulrich, R. G. 2000. The impact of genomics-based technologies on drug safety evaluation. Annu Rev Pharmacol Toxicol 40:335-352.
46. Zhou, T., Jia, X., Chapin, R. E., Maronpot, R. R., Harris, M. W., Liu, J., Waalkes, M. P., and Eddy, E. M. 2004. Cadmium at a non-toxic dose alters gene expression in mouse testes. Toxicol. Lett. 154(3):191-200.